A proposal: how to tell if a cell-free assay is predictive of therapeutic potency in vivo

In our speech at Prion2014, Sonia and I discussed a few of the possible routes toward prion therapeutics. The success to date with finding small molecule inhibitors of RML prions – cpd-b, anle138b, IND24 – argues that it might be … Continue reading

The overdrive hypothesis: is alpha cleavage key to keeping PrP in check?

Last year, I blogged a general introduction to alpha and beta cleavage, two events in the proteolytic processing of PrP. While the paradigm introduced in that post remains broadly correct, some refinements may be in order following recent work from … Continue reading